NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
43 trialsNCT07100730 2026-03-12
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05095376 2026-02-17
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT05904119 2026-02-17
LEGATO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT07145112 2025-10-09
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
University of California, Davis
Phase 1 Recruiting
NCT03970447 2025-09-09
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT04863950 2025-08-27
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT04762069 2025-05-04
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT06336291 2025-01-24
GLIOSTELLA
Philogen S.p.A.
Phase 2 Recruiting
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT06419946 2024-11-19
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Not yet recruiting
NCT04573192 2024-04-08
GLIOSTAR
Philogen S.p.A.
Phase 1/2 Recruiting
NCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT05410301 2023-04-21
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
University of Iowa
Phase NA Withdrawn
NCT00100802 2023-02-15
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Children's Oncology Group
Phase 2 Completed
NCT05017610 2022-12-02
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Emory University
Phase EARLY_PHASE1 Withdrawn
NCT02926222 2022-09-09
REGOMA
Istituto Oncologico Veneto IRCCS
Phase 2 Completed
NCT02843230 2022-04-08
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
Massachusetts General Hospital
Completed
NCT02076152 2021-07-30
FMISO PET Study of Glioblastoma
Massachusetts General Hospital
Phase NA Completed
NCT02765165 2021-07-23
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
Phase 1/2 Terminated
NCT03025893 2021-04-19
STELLAR
Amsterdam UMC, location VUmc
Phase 2/3 Unknown
NCT02678975 2021-03-18
Disulfiram in Recurrent Glioblastoma
Sahlgrenska University Hospital
Phase 2/3 Completed
NCT01290939 2021-02-15
Bevacizumab and Lomustine for Recurrent GBM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT01934361 2020-12-09
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Novartis
Phase 1 Completed
NCT02343406 2020-05-22
INTELLANCE-2
AbbVie
Phase 2 Completed
NCT01067469 2020-03-17
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT01562197 2019-01-24
AxiGII
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01860638 2018-04-30
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT01149109 2017-06-14
CeTeG
University Hospital, Bonn
Phase 3 Completed
NCT00005796 2015-03-25
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Indiana University
Phase 1 Completed
NCT00052455 2013-12-18
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00431561 2013-12-03
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Isarna Therapeutics GmbH
Phase 2 Completed
NCT00003788 2013-11-06
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
National Cancer Institute (NCI)
Phase 3 Unknown
NCT01737346 2012-12-03
Procarbazine and Lomustine in Recurrent Glioblastoma
Incheon St.Mary's Hospital
Phase 2 Unknown
NCT00948389 2012-08-31
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00504660 2012-01-11
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00503204 2009-11-25
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
AstraZeneca
Phase 1 Completed
NCT00068952 2008-04-01
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Pfizer
Phase 3 Completed